The arrival of GLP-1 and dual-incretin agonist medications has been the largest shift in weight-loss medicine globally in years. Korea\'s Ministry of Food and Drug Safety (MFDS) approved semaglutide for chronic weight management, and Wegovy launched in October 2024. Mounjaro (tirzepatide) was approved under a single brand for both diabetes and weight management. By 2026, a layer of Gangnam, Apgujeong, and Sinsa clinics actively prescribe these medications to both Korean patients and international visitors. This guide covers what is actually available and how Korean clinics handle prescription.
The medications
- Wegovy (semaglutide) — once-weekly injection, GLP-1 agonist. Launched in Korea late 2024.
- Mounjaro (tirzepatide) — once-weekly injection, dual GIP/GLP-1 agonist. MFDS-approved.
- Saxenda (liraglutide) — daily injection GLP-1 agonist. Available in Korea longer than the others.
- Ozempic (semaglutide for diabetes) — same active as Wegovy at lower doses; off-label use for weight loss is regulated.
- Retatrutide — investigational triple agonist not yet broadly approved.
Who is eligible
Korean clinical guidelines align broadly with international ones, with adjustment for Asian-specific BMI thresholds:
- BMI ≥ 30 — generally eligible for medical weight-loss pharmacotherapy.
- BMI ≥ 27 with comorbidities — diabetes, hypertension, dyslipidemia, sleep apnea — eligible.
- BMI ≥ 25 (Asian threshold) — Korean Society for the Study of Obesity recommends pharmacotherapy where lifestyle intervention has not produced adequate response. Some clinics extend prescription at this threshold.
- Diabetes — Mounjaro and semaglutide are approved for type 2 diabetes; weight loss is a known effect.
What Korean clinics prescribe
Reputable Korean weight-management clinics typically follow a structured protocol:
- Initial consultation with vital signs, BMI calculation, and medical history review.
- Baseline labs — fasting glucose, HbA1c, lipid panel, liver and kidney function, thyroid screen.
- Eligibility determination per Korean clinical criteria.
- Medication selection based on BMI, comorbidities, and patient preference.
- Starting dose with planned titration over weeks.
- Monthly follow-up for vitals, weight tracking, and side-effect management.
- Quarterly lab monitoring during active treatment.
Pricing in Korea (2026)
Approximate pricing at Gangnam clinics:
- Wegovy 0.25 mg starter pen: $170–$220.
- Wegovy higher doses (0.5–2.4 mg): $300–$500 per pen, varying with dose.
- Mounjaro: $400–$700 per pen depending on dose.
- Saxenda: $300–$500 per pen (daily injection, more pens used per month).
- Consultation fees: typically $80–$200 for initial consultation; lower for follow-ups.
- Lab work: $80–$200 depending on panel.
Pricing varies significantly with clinic tier and brand. Korean prices are competitive with most Western markets and substantially lower than US cash-pay pricing.
Side effects and safety considerations
Common side effects (early treatment):
- Nausea, occasional vomiting.
- Gastrointestinal upset, including reflux and constipation.
- Decreased appetite (the intended effect — but can be uncomfortable).
- Fatigue, especially during dose titration.
- Headache.
Less common but important:
- Pancreatitis — rare but serious; abdominal pain warrants immediate evaluation.
- Gallbladder issues — increased gallstone risk with rapid weight loss.
- Thyroid considerations — contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
- Diabetic retinopathy progression — risk in some diabetic patients with rapid glucose lowering.
For medical tourists
Practical considerations for international patients:
- Medications require continuation — typically 12+ months for sustainable benefit.
- Most Korean clinics require regular follow-up; remote prescription continuity needs planning.
- Importing medication across borders has regulatory and customs complications.
- Weight regain after discontinuation is common — establishing local prescription continuity in your home country before stopping is important.
- Best treated as a medication initiated and managed in your home country, with Korea as one consultation option among many.
The "diet pill" market vs. medical weight management
Korea\'s historical weight-loss market included a wide range of "diet pills" — phentermine, sibutramine derivatives, herbal compounds, and combination formulations — some of which have been linked to safety concerns. The 2026 distinction:
- Medical weight management — board-certified physician oversight, evidence-based medications (GLP-1 agonists), structured monitoring, lifestyle counseling.
- "Diet clinic" walk-in — variable practices; some offer rapid prescriptions of older stimulant-class medications without thorough evaluation.
For sustainable, safer weight loss, the medical-management model with GLP-1 and structured care is the appropriate choice.
Combination programs
Some Korean clinics package GLP-1 prescription with:
- IV infusion therapy — vitamin/mineral cocktails; effect on weight loss minimal but supportive.
- Body-contouring devices (EMSculpt, fat dissolving injections) for visible-fat-pocket management.
- Nutritional and lifestyle coaching.
- Sleep apnea screening and management for higher-BMI patients.
- Routine endocrine screening for thyroid and metabolic comorbidities.
What to ask in your consultation
- Am I clinically eligible based on Korean criteria?
- Which medication is appropriate for my BMI and history?
- What is the titration schedule?
- How will side effects be managed during titration?
- What lab monitoring will be done?
- What is the long-term plan, and how do I manage continuation in my home country?
- What is the discontinuation plan and weight-regain prevention?
Red flags
- Clinics offering medication without physician evaluation or labs.
- Pricing dramatically below pharmaceutical-supply cost — counterfeit GLP-1 is a known global problem.
- Pressure to start at high doses without titration.
- "Diet clinics" that combine stimulant-class older medications with GLP-1 — less evidence-based and more side-effect-prone.
- Lack of plan for long-term continuity after the trip.
The honest framing
GLP-1 medications are genuinely transformative for many patients with obesity. Korean clinics offer competent care at reasonable pricing within a regulated framework. The challenge for international patients is continuity — these medications work as long as you take them, and Korea-as-medical-tourism is best for initial consultation, lab work, and short-term supply, with home-country continuity essential for sustained results. Treat it as a starting point, not the entire plan.